Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Comparison of the Effects of the Thrombopoietin (TPO) Receptor Agonist Romiplostim in Patients with Immune Thrombocytopenia (ITP) for ≤1 Year Vs. >1 Year

David J Kuter, MD DPhil, Adrian Newland, Beng H Chong, MBBS, PhD, Francesco Rodeghiero, MD, Monica Tejeda Romero, Ingrid Pabinger, MD, Yuqi Chen, Kejia Wang, Bhakti Mehta, Melissa Eisen

Blood (2017) 130 (Supplement 1): 1055.

https://doi.org/10.1182/blood.V130.Suppl_1.1055.1055

Published: 2017

Journal Articles

Final Safety and Efficacy Data of Long-Term Open-Label Dosing of Subcutaneous (SC) Romiplostim in Children with Immune Thrombocytopenia (ITP)

Michael Tarantino, James B. Bussel, MD, Victor S. Blanchette, MD, Donald Beam, John Roy, Jenny M. Despotovic, DO, MS, Ashok Raj, Nancy Carpenter, Bhakti Mehta, Melissa Eisen

Blood (2017) 130 (Supplement 1): 14.

https://doi.org/10.1182/blood.V130.Suppl_1.14.14

Published: 2017

Journal Articles

A Single-Arm, Open-Label, Long-Term Efficacy and Safety Study of Subcutaneous (SC) Romiplostim in Children with Immune Thrombocytopenia (ITP)

John D. Grainger, MD MRCP, FRPATH, James B. Bussel, MD, Michael Tarantino, Nicola Cooper, MA, MD MRCP, FRCPath, Donald Beam, Jenny M. Despotovic, DO, MS, Alexey Maschan, MD PhD Professor, Nancy Carpenter, Melissa Eisen, Joseph Park

Blood (2017) 130 (Supplement 1): 2334.

https://doi.org/10.1182/blood.V130.Suppl_1.2334.2334

Published: 2017

Journal Articles

Safety and Efficacy of Long-Term Open-Label Dosing of Subcutaneous (SC) Romiplostim in Children with Immune Thrombocytopenia (ITP)

James B. Bussel, MD, Michael D. Tarantino, Victor S. Blanchette, Ashok Raj, Jenny Despotovic, Donald Beam, John Roy, Xuena Wang, Bhakti Mehta, Melissa Eisen

Blood (2016) 128 (22): 3738.

https://doi.org/10.1182/blood.V128.22.3738.3738

Published: 2016

Journal Articles

A Single-Arm, Open-Label, Long-Term Efficacy and Safety Study of Subcutaneous (SC) Romiplostim in Children with Immune Thrombocytopenia (ITP)

John Grainger, James B. Bussel, MD, Nichola Cooper, Michael Tarantino, Victor Blanchette, Jenny Despotovic, Alexey Maschan, MD PhD, Nancy Carpenter, Melissa Eisen, Bhakti Mehta

Blood (2016) 128 (22): 869.

https://doi.org/10.1182/blood.V128.22.869.869

Published: 2016

Journal Articles

Safety and Efficacy of Long-Term Open-Label Dosing of Subcutaneous (SC) Romiplostim in Pediatric Patients with Immune Thrombocytopenia (ITP)

Michael D Tarantino, MD, James B. Bussel, MD, Victor S. Blanchette, MD FRCP, Jenny M. Despotovic, DO, MS, Carolyn Bennett, Ashok Raj, MD, Bronwyn Williams, Donald Beam, Jaime Morales, Melissa J. Rose, DO, Kun Nie, Melissa Eisen, MD

Blood (2015) 126 (23): 3467.

https://doi.org/10.1182/blood.V126.23.3467.3467

Published: 2015

Journal Articles

Cost per Treatment Success of Thrombopoietin Receptor Agonists Vs "Watch and Rescue" Strategy for Treating Adult Non-Splenectomized Patients with Chronic Immune Thrombocytopenia: A US Payer Perspective

Xiaoyan Li, PhD, Anjali Sharma, MD, Xinke Zhang, MS, Marco Campioni, PhD, Kelly Fust, MS, Junji Lin, PhD, Anju Parthan, PhD, Xuena Wang, PhD, Richard Zur, PhD, Karynsa Cetin, MPH, Melissa Eisen, MD

Blood (2015) 126 (23): 4461.

https://doi.org/10.1182/blood.V126.23.4461.4461

Published: 2015

Journal Articles

Effect of Romiplostim on Health-Related Quality of Life in Children with Immune Thrombocytopenia and Associated Burden in Their Parents: Results from a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study

Susan D Mathias, MPH, Xiaoyan Li, PhD, Melissa Eisen, MD, Nancy Carpenter, MSc, Ross D Crosby, PhD, Victor S. Blanchette, MD FRCP

Blood (2015) 126 (23): 37.

https://doi.org/10.1182/blood.V126.23.37.37

Published: 2015

Journal Articles

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Safety and Efficacy of Romiplostim in Children with Immune Thrombocytopenia (ITP)

Michael D Tarantino, MD, James B. Bussel, Victor S. Blanchette, Jenny Despotovic, Carolyn Bennett, Ashok Raj, MD, Bronwyn Williams, Donald Beam, Jaime Morales, Melissa J. Rose, Nancy Carpenter, Kun Nie, Melissa Eisen

Blood (2015) 126 (23): 7.

https://doi.org/10.1182/blood.V126.23.7.7

Published: 2015

Journal Articles

Safety and Efficacy of Long-Term Open-Label Dosing of Romiplostim in Thrombocytopenic Pediatric Patients (Pts) with Immune Thrombocytopenia (ITP)

James B. Bussel, MD, Michael D. Tarantino, Amy Geddis, Michael F. Guerrera, Alan K. Ikeda, Kun Nie, Janet Franklin, Melissa Eisen

Blood (2014) 124 (21): 4184.

https://doi.org/10.1182/blood.V124.21.4184.4184

Published: 2014

Journal Articles

Safety and Efficacy Of Long-Term Open-Label Romiplostim Dosing In Thrombocytopenic Pediatric Patients With Immune Thrombocytopenia (ITP)

Michael D. Tarantino, MD, James B. Bussel, MD, Amy Geddis, MD, Michael F. Guerrera, MD, Alan K. Ikeda, MD, Kun Nie, PhD, Melissa Eisen, MD

Blood (2013) 122 (21): 3530.

https://doi.org/10.1182/blood.V122.21.3530.3530

Published: 2013

Journal Articles

Case Studies Of Remission In Adults With Immune Thrombocytopenia (ITP) Following Cessation Of Treatment With The TPO Receptor Agonist Romiplostim

James B. Bussel, MD, Xuena Wang, Melissa Eisen, MD

Blood (2013) 122 (21): 328.

https://doi.org/10.1182/blood.V122.21.328.328

Published: 2013

Journal Articles

A Systematic Literature Review and Meta-Analysis of the Risk of Thromboembolic Events in Patients with Immune Thrombocytopenia (ITP) in Observational Studies.

Wendy Langeberg, PhD, MPH, Melissa Eisen, MD, W. Marieke Schoonen, PhD, MPH, Laurence Gamelin, MD, PhD, Scott Stryker, MD, DrPH

Blood (2012) 120 (21): 2187.

https://doi.org/10.1182/blood.V120.21.2187.2187

Published: 2012

Journal Articles

Long-Term Use of Open-Label Romiplostim in Children with Chronic/Refractory Immune Thrombocytopenia (ITP)

James B Bussel, MD, George R. Buchanan, MD, David J. Gnarra, MD, Richard H. Ho, MD, MSCI, Kun Nie, Melissa Eisen, MD

Blood (2012) 120 (21): 621.

https://doi.org/10.1182/blood.V120.21.621.621

Published: 2012

Journal Articles

Clinical and Economic Outcomes Associated with Emergency Department Visits in Patients with Immune Thrombocytopenia,

Z John Lu, PhD, Mark D. Danese, MHS, PhD, Marc Halperin, Melissa Eisen, MD, Robert Deuson, PhD

Blood (2011) 118 (21): 4209.

https://doi.org/10.1182/blood.V118.21.4209.4209

Published: 2011

Journal Articles

Hospitalizations in Pediatric Patients with Immune Thrombocytopenia

Z John Lu, PhD, Mark D. Danese, MHS, PhD, Robert Herbert, Melissa Eisen, MD, Robert Deuson, PhD

Blood (2011) 118 (21): 170.

https://doi.org/10.1182/blood.V118.21.170.170

Published: 2011

Journal Articles

A Randomized, Double-Blind, Placebo-Controlled Phase 1/2 Study to Determine the Safety and Efficacy of Romiplostim in Children with Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP).

George R. Buchanan, MD, Lisa Bomgaars, MD, James B. Bussel, MD, Diane J. Nugent, MD, David J. Gnarra, MD, Victor S Blanchette, FRCP, Kun Nie, Melissa Eisen, MD, Dietmar Berger, MD, PhD

Blood (2009) 114 (22): 680.

https://doi.org/10.1182/blood.V114.22.680.680

Published: 2009

NARROW

Comparison of the Effects of the Thrombopoietin (TPO) Receptor Agonist Romiplostim in Patients with Immune Thrombocytopenia (ITP) for ≤1 Year Vs. >1 Year

Final Safety and Efficacy Data of Long-Term Open-Label Dosing of Subcutaneous (SC) Romiplostim in Children with Immune Thrombocytopenia (ITP)

A Single-Arm, Open-Label, Long-Term Efficacy and Safety Study of Subcutaneous (SC) Romiplostim in Children with Immune Thrombocytopenia (ITP)

Safety and Efficacy of Long-Term Open-Label Dosing of Subcutaneous (SC) Romiplostim in Children with Immune Thrombocytopenia (ITP)

A Single-Arm, Open-Label, Long-Term Efficacy and Safety Study of Subcutaneous (SC) Romiplostim in Children with Immune Thrombocytopenia (ITP)

Safety and Efficacy of Long-Term Open-Label Dosing of Subcutaneous (SC) Romiplostim in Pediatric Patients with Immune Thrombocytopenia (ITP)

Cost per Treatment Success of Thrombopoietin Receptor Agonists Vs "Watch and Rescue" Strategy for Treating Adult Non-Splenectomized Patients with Chronic Immune Thrombocytopenia: A US Payer Perspective

Effect of Romiplostim on Health-Related Quality of Life in Children with Immune Thrombocytopenia and Associated Burden in Their Parents: Results from a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Safety and Efficacy of Romiplostim in Children with Immune Thrombocytopenia (ITP)

Safety and Efficacy of Long-Term Open-Label Dosing of Romiplostim in Thrombocytopenic Pediatric Patients (Pts) with Immune Thrombocytopenia (ITP)

Safety and Efficacy Of Long-Term Open-Label Romiplostim Dosing In Thrombocytopenic Pediatric Patients With Immune Thrombocytopenia (ITP)

Case Studies Of Remission In Adults With Immune Thrombocytopenia (ITP) Following Cessation Of Treatment With The TPO Receptor Agonist Romiplostim

A Systematic Literature Review and Meta-Analysis of the Risk of Thromboembolic Events in Patients with Immune Thrombocytopenia (ITP) in Observational Studies.

Long-Term Use of Open-Label Romiplostim in Children with Chronic/Refractory Immune Thrombocytopenia (ITP)

Clinical and Economic Outcomes Associated with Emergency Department Visits in Patients with Immune Thrombocytopenia,

Hospitalizations in Pediatric Patients with Immune Thrombocytopenia

A Randomized, Double-Blind, Placebo-Controlled Phase 1/2 Study to Determine the Safety and Efficacy of Romiplostim in Children with Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only